BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Stock
Equities
2315
CNE100005D27
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.59 CNY | +0.31% |
|
-0.10% | -19.95% |
| May. 06 | Biocytogen Enters into Evaluation and Potential Licensing Agreement with Biocopy for TCR-mimic Antibodies | CI |
| Apr. 26 | Biocytogen Pharmaceuticals' Loss Narrows in 2023 | MT |
| Sales 2024 * | 919M 127M | Sales 2025 * | 1.15B 158M | Capitalization | 3.55B 491M |
|---|---|---|---|---|---|
| Net income 2024 * | -89M -12.29M | Net income 2025 * | 98M 13.53M | EV / Sales 2024 * | 4.01 x |
| Net Debt 2024 * | 133M 18.41M | Net cash position 2025 * | 64.26M 8.87M | EV / Sales 2025 * | 3.05 x |
| P/E ratio 2024 * |
-40.4
x | P/E ratio 2025 * |
37.1
x | Employees | 1,066 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 16.99% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +0.31% | ||
| 1 week | -0.10% | ||
| Current month | +10.10% | ||
| 1 month | +15.54% | ||
| 3 months | +14.71% | ||
| 6 months | -23.16% | ||
| Current year | -19.95% |
1 week
9.17
9.98
1 month
8.2010.60
Current year
5.7412.02
1 year
5.7424.45
3 years
5.7428.80
5 years
5.7428.80
10 years
5.7428.80
| Managers | Title | Age | Since |
|---|---|---|---|
Yue Lei Shen
CEO | Chief Executive Officer | - | 09-11-12 |
Liu Bin
DFI | Director of Finance/CFO | - | 20-01-04 |
Sabrina Wang
COO | Chief Operating Officer | - | 19-09-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Feng Mao Hua
BRD | Director/Board Member | 56 | 21-06-30 |
Yi Liang Wei
BRD | Director/Board Member | 53 | - |
Xiao Yan Liang
BRD | Director/Board Member | 58 | 20-11-30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-27 | 9.59 | +0.31% | 98,000 |
| 24-05-24 | 9.56 | -2.05% | 96,500 |
| 24-05-23 | 9.76 | +0.31% | 89,000 |
| 24-05-22 | 9.73 | +0.93% | 142,000 |
| 24-05-21 | 9.64 | +0.42% | 99,000 |
End-of-day quote Hong Kong S.E., May 26, 2024
More quotes
Biocytogen Pharmaceuticals Beijing Co Ltd is a company mainly engaged in drug development business and preclinical research. The Company operates its business through five segments. The Gene-Editing services segment provides the customized gene-editing services based on animals as well as cells. The Pre-clinical Pharmacology and Efficacy Evaluation segment provides preclinical pharmacology services for the evaluation of drug efficacy and toxicity. The Animal Models Selling segment breeds and sells the animal models for the external and internal use. The Antibody Development segment utilises its antibody discovery platforms to identify antibodies which have the potential to become drug candidates. The Innovative Drugs Development segment is engaged in research and development of innovative drugs with a focus on oncology and autoimmune disease therapeutics. The Company also conducts its business through the Other segment.
Calendar
2024-05-27
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
8.898
CNY
Average target price
14.21
CNY
Spread / Average Target
+59.75%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -19.95% | 491M | |
| +67.53% | 63.85B | |
| -0.77% | 41.83B | |
| +42.89% | 40.47B | |
| -10.02% | 27.17B | |
| +13.30% | 26.52B | |
| -22.79% | 18.69B | |
| +4.70% | 12.73B | |
| +24.10% | 12.11B | |
| +27.41% | 12.07B |
- Stock Market
- Equities
- 2315 Stock
